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CO R R E S POND EN C E
Incentive spirometry to prevent acute chest syndrome
in adults with sickle cell disease; a randomized controlled trial
To the Editor:
Acute chest syndrome (ACS) is a major complication in patients with
sickle cell disease (SCD), attributing to up to 25% of mortality.1 The
pneumonia-like complication frequently coincides with hospitalization
for vaso-occlusive crisis (VOC) and occurs in approximately 50% of
SCD patients. Besides the acute morbidity and mortality, chronically
impaired lung function in patients with recurrent ACS is described.2 A
frequently used definition for ACS is “presence of a new pulmonary
infiltrate on a chest X-ray in combination with fever or respiratory
symptoms in SCD patients”.1 Multiple factors have been demon-
strated to contribute to the development of ACS, including pulmonary
fat embolisms, bacterial/viral infections, thromboembolic disease and
hypoventilation due to thoracic bone infarction or the use of nar-
cotics, but in more than half of the patients the cause remains
unclear.2 Incentive spirometry is a non-invasive approach to prevent
hypoventilation and pulmonary complications by encouraging regular
deep inspiration. Two studies have reported this method to be effec-
tive as primary prevention of the development of ACS in SCD children
hospitalized for VOC.3,4 In the landmark study of Bellet et al.3 an
absolute risk reduction (ARR) of 36.8% in favor of spirometry was
found. Ahmad et al.4 observed an ARR of 14.1%(CI 1%-28%) by the
use of spirometry in a subgroup at high risk for ACS. However, these
studies were performed in pediatric patients and no studies have been
performed in adult SCD patients so far despite the pathophysiological
difference of ACS between these populations.2
In the present study, we aimed to evaluate the efficacy of incen-
tive spirometry to prevent ACS during VOC in hospitalized adult SCD
patients. Secondarily, we assessed whether specific clinical or labora-
tory characteristics were associated with an increased risk to
develop ACS.
We performed a prospective randomized controlled clinical trial
in two hospitals in the Netherlands between January 2010 and
August 2015. Patients were randomized to spirometry and standard
of care or standard of care only using the online randomization
software ALEA (ALEA version 2; 2010, Netherlands Cancer Institute,
Amsterdam, Netherlands). Standard of care consisted of pain man-
agement and hydration according to local protocols. Blood transfu-
sion, antibiotics and oxygen therapy were considered on clinical
indication by the attending physician. The spirometry group was
instructed to inhale through the spirometer (RespifloFS, Kendall)
every 2 hours between 8 AM and 10 PM. (10 inhalations each time)
until at least 24 hours after the pain had subsided. The study protocol
was approved by the Medical Ethical Review Committee of the par-
ticipating centers. Written informed consent was received from all
participants.
Consecutive adult SCD patients hospitalized for VOC were con-
sidered for inclusion. In order to select patients with the highest risk
of ACS, only patients with thoracic or back pain above the diaphragm
were included according to the study of Bellet et al.3 Pediatric
patients, patients with an ACS at presentation, pregnant women and
patients with a blood transfusion 3 months prior to admission were
excluded. Patients were allowed to enroll in the study more than
once, with a maximum of three enrollments. Hospitalizations of
multiple-included patients had to be separated by at least 4 weeks.
Note, VOC was defined as musculoskeletal and/or visceral pain that
could not be explained otherwise and required hospitalization for pain
management. ACS was defined as a new infiltrate on chest radio-
graph, accompanied by clinical symptoms including fever, pulmonary
complaints or desaturation. For this, chest X-rays were performed at
presentation and were repeated on day 5 of hospital admission or at
discharge, or earlier if clinically indicated. Blood samples were
retrieved at day one of hospitalization and were repeated before dis-
charge. Throat swabs were performed at presentation and analyzed
for bacterial and viral pathogens by multiplex polymerase chain reac-
tion (PCR). Blood cultures were determined to investigate possible
causality of specific pathogens.
The sample size was calculated at 31 patients per group with a
statistical power of at least 80%, at an alpha level of 0.05, to detect
a 30% lower rate of ACS in the spirometry group, comparable to
the study of Bellet et al., using Stata/SE, version 10.1 (Sampsi pro-
gram, StataCorp LP, Texas, USA). Continuous data are expressed
with corresponding means ±1 SD (SD) or with medians and (inter-
quartile range [IQR]). Categorical data were presented as numbers
(%). Comparisons between groups for numerical data were per-
formed with the Student t test or Mann-Whitney U test depending
on the distribution of data. All binary variables were compared using
the Pearsonʼs chi-Square test (χ2) or Fisherʼs exact test as
appropriate.
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We included 66 hospitalizations of 48 SCD patients. The baseline
characteristics are presented in Table 1. Eight patients were included
twice and five patients were included three times. Overall, ACS was
diagnosed in 11/66 (16.7%) hospitalizations. Laboratory results at
admission were comparable, except for leukocyte count: 10.1
[8.0-13.8] × 109/L vs 13.2[9.1-16.6] × 109/L in the spirometry and
control group, respectively (P = .031). Although not statistically signifi-
cant, hydroxycarbamide was used less in the spirometry group; 5/34
(14.7%) compared to controls 10/32 (31.3%; P = .109).
ACS developed in 5/34 (14.7%) hospitalizations in the spirometry
group compared to 6/32 (18.8%) in the non-spirometry group
(P = .660) indicating an ARR of 4.1% (CI −14% to 23%) in favor of spi-
rometry. When only unique patients were analyzed (48 individuals),
also no difference in ACS incidence between the treatment groups
was found (5/25 vs 5/23 in the spirometry and non-spirometry group,
respectively; P = .882). None of the throat swabs of patients develop-
ing ACS tested positive for pathogens. One ACS patient had a positive
blood culture (Streptococcus oralis/mitis).
Hospitalizations complicated by ACS had higher baseline LDH
levels (577[334-951]IU vs 353[246-553]IU; P = .004) and leukocyte
counts 15.2[11.1-19.7] × 109/L vs 10.8[8.0-13.8] × 109/L; P = .019)
compared with non-ACS hospitalizations (data non shown).
TABLE 1 Baseline characteristics




(N = 32) P
Baseline
Gender, female ― No. (%)a 14 (41.2) 15 (46.9)
Age ― yr 25.5 [23.0-32.0] 27 [23.3-41.8]
Genotype ― No. (%)
-Severe SCD (HbSS, HbSβ0
thalassemia)
22 (64.7) 24 (75.0)
-Mild SCD (HbSC, HbSβ+ thalassemia) 12 (35.3) 8 (25.0)
Medical history ― No. (%)
-Acute chest syndrome 11 (32.4) 10 (31.3)
-Frequent VOCb 19 (55.9) 20 (62.5)
Medication use ― no. (%)
-Hydroxycarbamide 5 (14.7) 10 (31.3)
Blood parameters emergency department
-Hemoglobin―g/dl 9.7 [8.5-11.0] 8.7 [7.6-10.6]
-Reticulocytes―% 10.9 [4.1-17.4] 9.8 [4.1-16.5]
-Platelets―×109/L 322.5 [175.5-426.0] 351.0 [270.8-419.3]
-Leukocytes―×109/L 10.1 [8.0-13.8] 13.2 [9.1-16.6]
-CRP―mg/L 7.3 [2.1-13.4] 6.0 [3.1-15.6]
-LDH―U/L 342.5 [246.0-517.0] 402.0 [304.0-661.0]
During hospitalization
Diagnosis of ACS―% (n) 14.7 (5) 18.8 (6) .660
Fever―% (n)c 20.6 (7) 31.3 (10) .322
Treatment with antibiotics―% (n) 41.2 (14) 50 (16) .472
Treatment with blood transfusion―% (n)d
All simple transfusions 14.7 (5) 21.9 (7) .450
Erythropheresis 11.8 (4) 6.3 (2) .673
Hospital stay―days 6.0 [4.0-7.0] 4.0 [3.0-8.5] .179
Readmission within 4 wk―% (n) 23.5 (8) 28.1 (9) .670
Abbreviations: ACS, acute chest syndrome; CRP, C-reactive protein; LDH, lactate dehydrogenase; VOC,
vaso-occlusive crisis.
aResults are expressed as n (%), means ± SD, or medians [interquartile range].
bFrequent VOC was defined as >2 hospital admissions due to VOC per year.
cFever was described as a temperature of ≥38.5°C for a single measurement, or a repeated temperature
of ≥38.0°C anytime during hospital admission.
dAll transfusions contains all hospitalizations during which at least one unit of packed cells was given.
Erythropheresis contains all patients from this group that received exchange transfusion.
2 CORRESPONDENCE
In this prospective randomized controlled trial, we were not able
to demonstrate a preventive effect of incentive spirometry on the
development of ACS in adult SCD patients. Our findings with a non-
significant ARR 4.1% for developing ACS contrast with Bellet et al.3
(ARR 36.8%) and Ahmad et al.4 (ARR 14.1%) in pediatric SCD patients.
The contrasting findings of our study in adult SCD patients as com-
pared to these previous studies could be explained by the etiological
difference in developing ACS between children and adults. This was
previously demonstrated in the cooperative study of SCD (CSSCD) in
nearly 1000 patients with SCD.5 Out of 1722 ACS episodes, the authors
concluded that, compared to children with SCD, ACS in adults was not
only associated with a greater disease severity and higher mortality rate,
but also with a different etiology. In this study, which was confirmed in
several other studies, the most frequent cause of ACS in children was a
viral or bacterial infection, whereas in adults fat emboli were more often
reported. In that same study, it was demonstrated that the incidence of
bacteremia appeared to be the highest in young children with an ACS
(14% in infants in comparison with 1.8% in patients between
10-66 years of age).5 Spirometry has been demonstrated to reduce atel-
ectasis and pneumonia in several studies in post-operative and COPD
patients. Although the validity of these studies has been questioned, the
fact that infection is a more frequent cause of ACS in children could
explain why spirometry seems to be more effective in the pediatric pop-
ulation. As spirometry is not expected to prevent fat emboli, which is
considered to be the main cause of ACS in adult SCD patients, this could
explain the lack of effectivity we found. Interestingly, none of the throat
swabs of ACS patients and only one blood culture became positive in
our study, confirming that infection is a rare cause of ACS in adults.
Several limitations should be mentioned. First, our study was
powered to detect an effect of 30% reduction in the incidence of
ACS. Therefore, the study may have been underpowered to find a
more moderate effect as demonstrated in a subgroup of patients in
the large study of Ahmad et al.4 Also the incidence of ACS was lower
than observed by Bellet et al.3 This could be explained by the fact that
we used stricter rules to diagnose ACS, for instance requiring a com-
plete lung segment to be affected, which may have led to a lower inci-
dence in our cohort. A second limitation, from a methodological point
of view, might be that patients were allowed to be randomized multi-
ple times. However, analyses of only ACS episodes restricted to single
randomizations (n = 48) showed similar results. Lastly, there was a
trend towards more sparse use of hydroxyurea in the spirometry
group which may have influenced the outcome given the preventative
effect of hydroxyurea on ACS. Although a direct effect on the devel-
opment of ACS cannot be excluded, the preventive effect on ACS is
most likely due to prevention of VOC primarily as indicated by the
identical rate of effect on VOC and ACS prevention in the landmark
study of Charache et al.6
In conclusion, our study was unable to demonstrate a preven-
tive effect of incentive spirometry on the development of ACS in
adult sickle cell patients. The findings emphasize the need for large
prospective studies evaluating the use of incentive spirometry in
adults.
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